An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
This study, known as a Phase IV trial, is specifically for people with a serious brain tumour called glioblastoma multiforme. Researchers are looking closely at how their immune system, which is the body's natural defence, changes both before and during treatment with a medicine called bevacizumab (also known as Avastin). The main goals are to see if these immune system changes can help predict how the disease might progress, how long people live without the tumour growing back in the same spot, how long they live without the tumour getting worse, and overall survival rates. They are also investigating tiny particles in the blood to learn more about the disease.
At a glance
What is this study about?
This study is particularly for people who have been diagnosed with a serious type of brain tumour called glioblastoma multiforme. It's called an 'open label, Phase IV' study. 'Open label' means that both you and your doctors will know you are receiving bevacizumab. 'Phase IV' means this medicine is already approved for use, and researchers are now gathering more information about its effects in a real-world setting. They want to understand how your body's natural defence system (your immune system) changes during the course of the illness.
The main aim is to see if changes in your immune system can help predict how your condition might develop. For example, they want to find out if these changes can tell them how long you might live without the tumour returning in the exact same spot, how long you live without the tumour growing bigger or spreading, and your overall survival. This information is really important because it could help doctors understand the disease better and personalise treatments in the future.
In addition to looking at your immune system, the researchers will also be examining tiny particles in your blood. These particles can contain genetic material and proteins that might give further clues about your tumour and how it responds to treatment. By understanding these tiny details, they hope to improve future care for people with glioblastoma multiforme.
Key takeaways
- This study focuses on glioblastoma multiforme, a serious brain tumour.
- It investigates how your body's immune system changes during treatment with bevacizumab.
- Researchers hope to learn more about how the disease progresses and how to predict treatment response.
- Participation involves receiving bevacizumab infusions and regular monitoring.
- The study aims to improve future care for people with glioblastoma multiforme.
Who may be eligible?
To be part of this study, you must be at least 18 years old. There is no upper age limit, meaning older adults can also take part. The study is open to both men and women.
The most important requirement is that you have been diagnosed with glioblastoma multiforme. The research team will check other specific medical details to make sure this study is the right fit for you and that taking part is safe.
- Are you 18 years old or older?
- Do you have a diagnosis of glioblastoma multiforme?
- Are you able to attend regular hospital or clinic visits?
- Are you willing to receive bevacizumab infusions?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part, you will receive bevacizumab infusions, which are given directly into your vein. The study will involve regular visits to the hospital or clinic where doctors and nurses will monitor your health closely. This will include blood tests to check your immune system and the tiny particles mentioned earlier. You will also have regular scans to monitor your tumour.
The exact number and timing of visits will be explained by the study team, as will the total duration of your participation. Throughout the study, the medical team will be there to support you and answer any questions you have.
Potential risks and benefits
Locations (1)
- —Hungary
Common questions
What is glioblastoma multiforme?
It's a serious type of brain tumour.
What is bevacizumab (Avastin)?
It's a medicine given through an infusion that is used to treat certain cancers.
What does 'immunological changes' mean?
It refers to how your body's natural defence system (immune system) reacts during the illness and treatment.
Will I know if I'm getting the treatment?
Yes, this is an 'open label' study, meaning you and your doctors will know you're receiving bevacizumab.
Is this a new treatment?
No, bevacizumab is already approved, but this study gathers more information about its effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.